Current Law Journal Content
Washington & Lee Law School
  Current Law Journal Content
                  an index to legal periodicals
 


  Biotechnology Law Report
  Volume 26, Number 1, February 2007
  homepage                   other issues
 

  • Recent Developments in European Patent Law
  • Stem Cell Patents: Does T 0866/01 (“Euthanasia Compositions”) of An Appeal Board of The EPO Provide The Answers for The Enlarged Board of Appeal Case G 2/06 (“Primate Embryonic Stem Cells”)?
        Franz-Josef Zimmer
        p.1-4                                                                                      +cite        
  • Reduction to Practice: All Inventions Are Created Equal: Refinement of T 1329/04 in Favor of The Completeness of DNA Inventions without Wet Biology Experiments
        Hans-Rainer Jaenichen
        p.5-13                                                                                    +cite        
  • Comments on Recent Cases
        Harold C. Wegner
        p.14-15                                                                                  +cite        

  • Regulatory Affairs—Pharmaceutical
  • Senate Finally Approves Von Eschenbach as FDA Commissioner; FDA Proposes New Rules for Access to Experimental Drugs; Submitting Genomics Data to FDA; GAO Looks at Drug Development; Too Much Epo?
        p.16-18                                                                                  +cite    

  • Clinical Trials
  • New Prophylactic Agent for Rabies Enters Phase I; Trigen Launches Phase I Investigation of Platelet Inhibitor; Trial of Adult Stem Cells Aimed at Back Pain
        p.19-19                                                                                  +cite    

  • Regulatory Affairs—Agricultural and Environmental
  • Lawsuits over Liberty Link Rice Consolidated; EPA Fines Syngenta for Distributing Unapproved Corn; U.K. Approves Field Trials of Blight-Resistant Potato; WTO Chides Europe for Stance on Genetically Engineered Crops; FDA Approves Use of Cloned Animals for Food
        p.20-21                                                                                  +cite    

  • Patents
  • Setback for ABI And Caltech; Thailand “Breaks” Another Anti-HIV Patent; Pfizer Can Sell Exubera; “Rebel” Is A Generic Name And Cannot Be Registered as A Trademark; India to Offer Incentives for Drug Patents; Protiva Drops One Suit to Pursue Others; A New Patent on Technology for Gene Therapy
        p.22-24                                                                                  +cite    

  • Patent Litigation
  • Will Supreme Court Redefine “Obvious”?; Divided CAFC Decides Not to Hear Amgen— Transkaryotic En Banc; Ouch! Invitrogen Awarded Triple Damages; Insmed Is Infringing Genentech Patent; Agilent, Affymetrix Agree to Mediation; CAFC Temporarily Halts Sales of Generic Anabolic Steroid; Short Story:News from Depomed
        p.25-27                                                                                  +cite    

  • Financial And Shareholder Affairs
  • Immune Response Settles Shareholder Suits; Two Gene Therapy Companies to Merge
        p.28                                                                                        +cite    

  • Scientific Misconduct
  • Sunderland Pleads Guilty to Violation of Conflict of Interest Regulations; More Charges against Icelandic Researchers
        p.29                                                                                        +cite    

  • Science and Society
  • Law against Animal Rights Extremism Strengthened; Future of Vaxgen in Doubt after DHHS Cancels Anthrax Vaccine Contract
        p.30                                                                                        +cite    

  • Professional Practice
  • Federal Courts Now Require Delivery of All Electronic Information to Opponents
        p.31                                                                                        +cite    

  • Electronic Biotechnology
  • Comprehensive Database of SNP Analyses Established
        p.32                                                                                        +cite    
  • Bibliography
        p.33-35                                                                                  +cite    
  • On The Move
        p.36-39                                                                                  +cite    

  • Texts
  • Expanded Access to Investigational Drugs for Treatment Use: Proposed Rule
        p.40-66                                                                                  +cite    
  • Draft Preliminary Concept Paper: Recommendations for The Generation And Submission of Genomic Data
        p.67-76                                                                                  +cite    
  • In Re Pennington Seed, Inc. (Serial No. 76/289,621) (06-1133)
        p.77-81                                                                                  +cite    
  • Report to Congressional Requesters: New Drug Development—Science, Business, Regulatory, And Intellectual Property Issues Cited as Hampering Drug Development Efforts
        p.82-95                                                                                  +cite    
  • Amgen Inc., v. Hoechst Marion Roussel, Inc. And Transkaryotic Therapies, Inc. (05-1157)
        p.96-101                                                                                +cite    
  • Coming Events
        p.102-105                                                                              +cite